Evaluation of Protein Oxidation in Bipolar Patients Taking Lithium and Valproat Treatment

Year 2013, Volume: 22 Issue: 3, 223 - 226, 01.12.2013

Funda Akpınar Figen Narin Saliha Demirel Özsoy

Abstract

In this study importance of advanced oxidation protein
product (AOPP) levels in the determination of oxidative
stress in the patients taking lithium, valproat treatment
and healthy people was investigated.
Forty bipolar patients (20 patients taking lithium and
20 patients taking valproat) and 20 healthy persons
were included in this study. AOPP levels were
measured with spectrophotometric methods. KruskalWallis test was used for statistical evaluation and p
value less than 0.05 was accepted statistically
significant.
AOPP levels of bipolar patients were not found
statistically significant when compared with control
group (p>0.05).
In conclusion; results were partially compatible with
the results of other studies about increased oxidative
stress in bipolar disorders. However, it was thought
that oxidative stress could not completely explain the
pathophysiology of bipolar disorders.

Keywords

Bipolar disorder, lithium, valproate, advanced protein oxidation product

LİTYUM VE VALPROAT ALAN BİPOLAR HASTALARDA PROTEİN OKSİDASYONUNUN DEĞERLENDİRİLMESİ

Abstract

Bu çalışmada; sağlıklı kişiler ile, lityum ve valproat alan
bipolar hastalarda oksidatif stresi değerlendirmek amacıyla protein ileri oksidasyon ürünü (AOPP) düzeyinin
önemi araştırıldı.
Lityum kullanan 20 hasta ile, valproat kullanan 20 hasta
olmak üzere toplam 40 bipolar bozukluğu olan hasta ve
20 sağlıklı birey çalışmaya dahil edildi. AOPP düzeyi
spektrofotometrik metodlarla ölçüldü. İstatistiksel değerlendirme için Kruskal-Wallis testi kullanıldı. 0.05’den
küçük p değeri istatistiksel olarak anlamlı kabul edildi.
Bipolar bozukluğu olan hastalarda ölçülen serum AOPP
düzeyi kontrol grubu ile karşılaştırıldığında aralarında
istatistiksel olarak anlamlı fark bulunmamıştır (p>0.05).
Çalışmamızın sonucu, bipolar bozuklukta artmış
oksidatif stresi gösteren diğer çalışmalarla kısmen
uyumluluk gösterse de oksidatif stresin tam olarak
bipolar bozukluk patofizyolojisini açıklamadığını düşündürmektedir.

Keywords

Bipolar bozukluk, lityum, valproat, protein ileri oksidasyon ürünü

References

• Angst J, Ernst C. Current concepts of the classification of affective disorders. Int Clin Psychopharmacol 1993; 8: 211-215.
• Schou M, Baastrup PC. Lithium treatment of manic depressive disorder. Dosage and control. JAMA 1967; 201:696-698.
• Tondo L, Baldessarini RJ, Floris G. Long-term clinical effectiveness of lithium maintenance treatment in types I and II bipolar disorders. Br J Psychiatry 2001; 41: 184-190.
• Bowden CL, Calabrase JR, McElroy SL, et al. A randomized, placebo-contolled 12- month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintanence Study Group. Arch Gen Psychiatry 2000; 57: 481- 489.
• Emrich HM, Wolf R. Valproate treatment of mania. Prog Neuropsychopharmacol Biol Psychiatry 1992; 16: 691-701.
• Jope RS. A bimodal model of the mechanism of action of lithium. Mol Psychiatry 1999; 4: 21-25.
• Witko-Sarsat V, Friendlander M, Capeillere-Blandin C, et al. Advanced oxidation protein products as a novel marker of oxidative stres in uremia. Kidney Int 1996; 49: 1304-1313.
• Mahadik SP, Mukherjee S. Free radical pathology and antioxidant defense in schizoprenia. Schizophr Res. 1996; 19: 1-17.
• Bains JS, Shaw CA. Neurodegenerative disorders in humans: the role of glutathione in oxidative stres- mediated neuronal death. Brain Res 1997; 3: 335- 358.
• Sarandöl E, Sarandöl A, Altın A, ve ark. Majör Depresif Bozukluk Oksidatif Stres ile Seyreder 19. Ulusal Biyokimya Kongresi Bildiri Kitabı, 2005; ss 22-25.
• Maes M, de Vos N, Pioli R, et al. Lower serum vita- min E concentrations in major depression. Another marker of lowered antioxidant defenses in that illness. J Affect Disord 2000; 58: 24-26.
• Keller RJ, Halmes NC, Hinson JA, et al. Immunochemical detection of oxidized proteins. Chem Res Toxicol 1993; 6: 430-433.
• Akyol Ö. Oxidative stress in schizophrenia. Kocatepe Tıp Dergisi 2004; 4: 15-25.
• Tsuboi H, Tatsumi A, Kinae N, et al. Possible connections among symptoms, lipid modulation and antioxidants Hamamatsu Japan 2005: 431-2102. depressive
• Dubinina EE, Morozova MG, Leonova NV, et al. Oxidative modification of blood proteins in patient with depersonalization) ;Vopr Med Khim 2000; 46: 398- 409. (depression,
• Conrad CC, Marshall PL, Talend JM, et al. Oxidized proteins in Alzheimer’s plasma. Biochem Biophys Res Commun 2000; 275: 678-681.
• Smith MA, Richey PL, Taneda S, et al. Advanced Maillard reaction end products, free radicals, and protein oxidation in Alzheimer's disease. Ann N Y Acad Sci 1994; 738: 447-454.
• Zafrilla P, Mulero J, Xandri JM, et al. Oxidative stress in Alzheimer patients in different stages of the disease Curr Med Chem 2006; 13:1075-1083.
• Alam Z I, Daniel S E, Lees A J, et al. A generalised increase in protein carbonyls in the brain in Parkinson’ but not incidental Lewry Body Disease Journal of Neurochemistry 1997: 69: 1326-1329.
• Guochuan Tsai MD, Donald C, et al. Markers of glutamatergic neurotransmission and oxidative stress associated with tardive dyskinesia Am J Psychiatry 1998; 155: 1207-1213.